In PYC's September update, Shri (Chief of R & D), commented in relation to the Phase 1 study for RP11, (Single ascending dose, SAD), that they were going to push for approval to add an extra cohort for ~90 microgram. The reasoning was that PYC had already generated safety data in monkey eyes for doses of 50 micrograms, which correlates to doses up to 100 microgram in humans. Maybe that push for the extra cohort in the current Phase 1 study could be part of a strategy to bolster the safety outcomes in a way which may provide multiple ocular treatment options.
My post here, I think, supports and links to the ocular treatments that Medicine Man is suggesting, as additional indications, that PYC may go after?
Expand
(20min delay)